Who Paid My Doc
Assal Rahimi
Radiation Oncology Dallas, TX Medical Doctor
NPI 1124232343 CMS profile 936258
5323 Harry Hines Blvd, Dallas, TX 75390
General payments
$42,836
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$105,000
Through program year 2025, Assal Rahimi of Dallas, TX is reported in the CMS Open Payments database as having received $42,836 across 42 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $105,000 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,000 | 1 | |
| 2024 | General | $1,156 | 3 | |
| 2023 | General | $4,545 | 3 | |
| 2022 | General | $10,669 | 13 | |
| 2021 | General | $7,522 | 5 | |
| 2020 | General | $15,375 | 15 | |
| 2019 | General | $2,568 | 2 |
Beside peers
- Assal Rahimi
- Radiation Oncology median
- Middle half of Radiation Oncology
- National median
In program year 2025, general payments to Assal Rahimi were reported at $1,000. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.
Show as a table
| Year | Assal Rahimi | Radiation Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,568 | $138 | $48–$462 | $163 |
| 2020 | $15,375 | $79 | $26–$262 | $114 |
| 2021 | $7,522 | $119 | $37–$358 | $132 |
| 2022 | $10,669 | $139 | $43–$424 | $149 |
| 2023 | $4,545 | $167 | $57–$473 | $160 |
| 2024 | $1,156 | $168 | $56–$541 | $164 |
| 2025 | $1,000 | $172 | $61–$514 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 20 billing codesPaid by Medicare
$74,353
Medicare patients
95
Services billed
915
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Cancer | 75% | |
| High blood pressure | 73% | |
| Arthritis | 63% | |
| Osteoporosis | 41% | |
| Depression | 20% | |
| Diabetes | 19% | |
| Ischemic heart disease | 16% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
42 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Radiation Oncology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Radiation Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.